Literature DB >> 9501012

Early glycoxidation damage in brains from Down's syndrome.

P Odetti1, G Angelini, D Dapino, D Zaccheo, S Garibaldi, F Dagna-Bricarelli, G Piombo, G Perry, M Smith, N Traverso, M Tabaton.   

Abstract

In Down's syndrome, the presence of three copies of chromosome 21 is associated with premature aging and progressive mental retardation sharing the pathological features of Alzheimer disease. Early cortical dysgenesis and late neuronal degeneration are probably caused by an overproduction of amyloid beta-peptide, followed by an increased cellular oxidation. Interestingly, chromosome 21 codes for superoxide-dismutase and amyloid beta precursor resulting, in Down's syndrome, in an overflow of these gene products and metabolites. We studied Down's fetal brain cortex to evaluate the presence and amount of lipid and protein oxidation markers; moreover, we quantified two forms of glycation end products that are known to be involved in the process of cellular oxidation. All these parameters are significantly increased in Down's fetal brains in comparison to controls, providing the evidence that accelerated brain glycoxidation occurs very early in the life of Down's syndrome subjects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9501012     DOI: 10.1006/bbrc.1998.8186

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  26 in total

1.  Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome.

Authors:  Giovanna Cenini; Amy L S Dowling; Tina L Beckett; Eugenio Barone; Cesare Mancuso; Michael Paul Murphy; Harry Levine; Ira T Lott; Frederick A Schmitt; D Allan Butterfield; Elizabeth Head
Journal:  Biochim Biophys Acta       Date:  2011-10-08

Review 2.  Oxidative imbalance in Alzheimer's disease.

Authors:  Xiongwei Zhu; Hyoung-Gon Lee; Gemma Casadesus; Jesus Avila; Kelly Drew; George Perry; Mark A Smith
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

Review 3.  Indices of metabolic dysfunction and oxidative stress.

Authors:  Gemma Casadesus; Paula I Moreira; Akihiko Nunomura; Sandra L Siedlak; William Bligh-Glover; Elizabeth Balraj; Grace Petot; Mark A Smith; George Perry
Journal:  Neurochem Res       Date:  2007-03-07       Impact factor: 3.996

Review 4.  The role of environmental exposures in neurodegeneration and neurodegenerative diseases.

Authors:  Jason R Cannon; J Timothy Greenamyre
Journal:  Toxicol Sci       Date:  2011-09-13       Impact factor: 4.849

5.  Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation.

Authors:  Ira T Lott; Eric Doran; Vinh Q Nguyen; Anne Tournay; Elizabeth Head; Daniel L Gillen
Journal:  Am J Med Genet A       Date:  2011-07-07       Impact factor: 2.802

6.  Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease.

Authors:  Fabio Di Domenico; Gilda Pupo; Antonella Tramutola; Alessandra Giorgi; Maria Eugenia Schininà; Raffaella Coccia; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2014-03-25       Impact factor: 7.376

Review 7.  Antioxidants in Down syndrome.

Authors:  Ira T Lott
Journal:  Biochim Biophys Acta       Date:  2011-12-21

Review 8.  Mitochondrial dynamics in Alzheimer's disease: opportunities for future treatment strategies.

Authors:  David J Bonda; Xinglong Wang; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  Drugs Aging       Date:  2010-03-01       Impact factor: 3.923

Review 9.  Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications.

Authors:  D Allan Butterfield; Marzia Perluigi; Tanea Reed; Tasneem Muharib; Christopher P Hughes; Renã A S Robinson; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2012-01-18       Impact factor: 8.401

Review 10.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.